Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer
Authors
Keywords
MicroRNAs, Cancer treatment, Cancer chemotherapy, Adenocarcinomas, Chemotherapy, Surgical and invasive medical procedures, Histology, Gynecologic surgery
Journal
PLoS One
Volume 12, Issue 3, Pages e0174300
Publisher
Public Library of Science (PLoS)
Online
2017-03-24
DOI
10.1371/journal.pone.0174300
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Current status on microRNAs as biomarkers for ovarian cancer
- (2016) Kira Philipsen Prahm et al. APMIS
- Clinical Impact of a Novel MicroRNA Chemo-Sensitivity Predictor in Gastrooesophageal Cancer
- (2016) Mette Winther et al. PLoS One
- PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions
- (2015) Jonathan A Ledermann et al. BRITISH JOURNAL OF CANCER
- The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells
- (2015) Anamaria Brozovic et al. Molecular Oncology
- MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells
- (2015) Hong-Min Zhao et al. TUMOR BIOLOGY
- Development and Blind Clinical Validation of a MicroRNA Based Predictor of Response to Treatment with R-CHO(E)P in DLBCL
- (2015) Steen Knudsen et al. PLoS One
- MicroRNA-370 suppresses proliferation and promotes endometrioid ovarian cancer chemosensitivity to cDDP by negatively regulating ENG
- (2014) Xiao-Ping Chen et al. CANCER LETTERS
- Ectopic over-expression of miR-429 induces mesenchymal-to-epithelial transition (MET) and increased drug sensitivity in metastasizing ovarian cancer cells
- (2014) Lijuan Wang et al. GYNECOLOGIC ONCOLOGY
- BAG3 upregulates Mcl-1 through downregulation of miR-29b to induce anticancer drug resistance in ovarian cancer
- (2014) Asuka Sugio et al. GYNECOLOGIC ONCOLOGY
- MiR-200c and HuR in ovarian cancer
- (2013) Silvia Prislei et al. BMC CANCER
- Downregulation ofmiR-29contributes to cisplatin resistance of ovarian cancer cells
- (2013) Pei-Ning Yu et al. INTERNATIONAL JOURNAL OF CANCER
- A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis
- (2013) A. Vecchione et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- microRNAs in cancer management
- (2012) Yi W Kong et al. LANCET ONCOLOGY
- miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells
- (2012) M T M van Jaarsveld et al. ONCOGENE
- Integrated Analyses of microRNAs Demonstrate Their Widespread Influence on Gene Expression in High-Grade Serous Ovarian Carcinoma
- (2012) Chad J. Creighton et al. PLoS One
- Bevacizumab and ovarian cancer
- (2012) Agustin Garcia et al. Therapeutic Advances in Medical Oncology
- miR-141 and miR-200a act on ovarian tumorigenesis by controlling oxidative stress response
- (2011) Bogdan Mateescu et al. NATURE MEDICINE
- The miR-200 family controls -tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients
- (2010) S. Leskela et al. ENDOCRINE-RELATED CANCER
- MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells
- (2010) Zhimin Li et al. GYNECOLOGIC ONCOLOGY
- Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma
- (2010) María Ángeles Castilla et al. JOURNAL OF PATHOLOGY
- The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer
- (2010) Lori E. Weinberg et al. JOURNAL OF SURGICAL ONCOLOGY
- Loss of miR-200c Expression Induces an Aggressive, Invasive, and Chemoresistant Phenotype in Non-Small Cell Lung Cancer
- (2010) P. Ceppi et al. MOLECULAR CANCER RESEARCH
- Up-regulation of miR-200 and let-7 by Natural Agents Leads to the Reversal of Epithelial-to-Mesenchymal Transition in Gemcitabine-Resistant Pancreatic Cancer Cells
- (2009) Y. Li et al. CANCER RESEARCH
- Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
- (2009) Kristine R. Broglio et al. JNCI-Journal of the National Cancer Institute
- MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents
- (2009) D. R. Cochrane et al. MOLECULAR CANCER THERAPEUTICS
- Management of Recurrent Ovarian Carcinoma: Current Status and Future Directions
- (2009) Lainie P. Martin et al. SEMINARS IN ONCOLOGY
- MicroRNA Microarray Identifies Let-7i as a Novel Biomarker and Therapeutic Target in Human Epithelial Ovarian Cancer
- (2008) N. Yang et al. CANCER RESEARCH
- MicroRNA Expression Profiles in Serous Ovarian Carcinoma
- (2008) E. J. Nam et al. CLINICAL CANCER RESEARCH
- Role of microRNAs in drug-resistant ovarian cancer cells
- (2008) Antonio Sorrentino et al. GYNECOLOGIC ONCOLOGY
- MicroRNA in Cancer Prognosis
- (2008) Frank J. Slack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer
- (2008) L. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Suppression of non-small cell lung tumor development by the let-7 microRNA family
- (2008) M. S. Kumar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now